MD

Pediatrix Medical Group, Inc. - 10-Q Summary (Period Ended Sep 30, 2003)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2003, for Pediatrix Medical Group, Inc., a Florida-based corporation providing pediatric medical services. The Company operates through subsidiaries and management arrangements with professional associations. During the nine months ended September 30, 2003, the Company completed the acquisition of an independent laboratory specializing in newborn metabolic screening and five physician group practices.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 18.8% ($23.0 million) for the three months and 17.2% ($59.4 million) for the nine months compared to the prior year periods. Approximately 34.3% of the quarterly increase and 30.6% of the nine-month increase were attributable to acquisitions.
• Same-Unit Growth: Same-unit revenue increased 12.5% (quarterly) and 12.3% (nine-month), driven by billing code changes, increased neonatal intensive care patient days, and modest price increases.
• Expenses: Practice salaries and benefits rose 17.5% (quarterly) and 17.6% (nine-month) due to incentive compensation, new staff for acquisitions, and higher insurance costs. General and administrative expenses increased 13.5% (quarterly) and 8.2% (nine-month), partly due to legal costs associated with an FTC investigation.
• Liquidity: Cash and cash equivalents decreased significantly from $73.2 million at year-end 2002 to $10.4 million at September 30, 2003. This reduction was primarily due to $100 million in share repurchases and $63.3 million in acquisition payments.
• Debt: The Company utilized its $100 million line of credit, with an outstanding balance of $14.5 million at September 30, 2003, compared to zero at December 31, 2002.

Guidance, Outlook, Risks, and Contingencies

Outlook: Management anticipates that funds from operations, cash on hand, and the line of credit will be sufficient to meet working capital and capital expenditure requirements for the next 12 months. The Company is evaluating a proposal for a new revolving credit facility to replace the current line maturing in August 2004, though no assurance of terms is provided.

Risks and Contingencies:

• Regulatory Investigations: The Company is subject to an active and ongoing investigation by the Federal Trade Commission (FTC) regarding competition issues related to the 2001 acquisition of Magella Healthcare. Additionally, federal investigators are conducting civil investigations into the Company's Medicaid and TRICARE billing practices nationwide.
• Legal Proceedings: Five purported federal securities law class action cases were voluntarily dismissed without prejudice in October 2003. The Company faces routine medical malpractice claims, which are generally expected to be covered by insurance.
• Accounting Policies: The Company uses the intrinsic value method for stock-based compensation. Pro forma net income would be lower if fair value accounting (FAS 123) were applied.

Investor Verification Checklist

• Verify the status and potential financial impact of the ongoing FTC investigation and federal billing practice inquiries (Medicaid/TRICARE).
• Confirm the terms and availability of the new revolving credit facility being evaluated to replace the current line of credit maturing in August 2004.
• Assess the integration progress and revenue contribution of the five physician groups and the metabolic screening laboratory acquired in 2003.
• Review the sustainability of the 12%+ same-unit revenue growth rate given the reliance on billing code changes and price increases.
• Monitor the Company's cash burn rate relative to its current cash balance of $10.4 million and the $14.5 million line of credit draw.